Diseases and Abnormalities at or Before Birth

All Conditions

Heart and Blood Diseases

Neoplasms

Blood and Lymph Conditions

Rare Diseases

Congenital Abnormalities

Vascular Malformations

Lymphangioma

Lymphatic Abnormalities

Cardiovascular Abnormalities

Neoplasms by Histologic Type

Lymphatic Diseases

Lymphatic Malformations

Microcystic Lymphatic Malformation

Anti-Infective Agents

Antineoplastic Agents

All Drugs and Chemicals

Sirolimus

Anti-Bacterial Agents

Antibiotics, Antitubercular

Clotrimazole

Miconazole

Antifungal Agents

Immunosuppressive Agents

Immunologic Factors

microcystic \& mixed lymphatic malformation

patients with Microcystic , Mixed Lymphatic and Vascular Malformations will be given sirolimus 1 mg oral tab for 3-6 months with follow up of lesion size by clinical exam \& ultrasound \& MRI to compare lesion size before \& after use of the drug with observation of potential side effects \& after exclusion of it before use of the drug

Sirolimus 1Mg Oral Tablet

Tarek A Abd elsalam, resident

Mohamed yousef, Ass. Prof.

Magdy M Amin, professor

Lympho-vascular malformations result from errors in embryologic vasculogenesis involving capillaries, veins, arteries, lymphatics, or a combination of these. Infantile haemangiomas \& Vascular malformations like : Capillary malformations \& Venous malformations : they increase in size and never regress on their own. \& They are generally present at birth, they enlarge in response to infection, hormonal changes or trauma . Lymphatic malformations can be classified into macrocystic (cyst diameter \>1cm), microcystic (cyst diameter \<1 cm), or mixed , in macrocystic lymphatic malformations, surgery and sclerotherapy are effective . Surgery of microcystic lymphatic malformations remains challenging due to their infiltrative nature \& Sclerotherapy is often impossible. As especially large microcystic and mixed malformations are still a therapeutic challenge, pharmaceutical treatment as sirolimus is used in last years as main line of treatment with great efficacy.

Lympho-vascular malformations result from errors in embryologic vasculogenesis involving capillaries, veins, arteries, lymphatics, or a combination of these. Infantile haemangiomas \& Vascular malformations like : Capillary malformations \& Venous malformations : they increase in size and never regress on their own. \& They are generally present at birth, they enlarge in response to infection, hormonal changes or trauma . Lymphatic malformations can be classified into macrocystic (cyst diameter \>1cm), microcystic (cyst diameter \<1 cm), or mixed , in macrocystic lymphatic malformations, surgery and sclerotherapy are effective . Surgery of microcystic lymphatic malformations remains challenging due to their infiltrative nature \& Sclerotherapy is often impossible. As especially large microcystic and mixed malformations are still a therapeutic challenge, pharmaceutical treatment as sirolimus is used in last years as main line of treatment with great efficacy. Sirolimus is a natural macrolide isolated from a bacteria strain of the Streptomyces genus \& Streptomyces hygroscopicus . It was initially used as an antibiotic and antifungal agent, subsequent studies have revealed impressive cytostatic, antiproliferative, and immunosuppressive properties . Sirolimus not only prevents the growth of abnormal lymphatics but also induces the partial regression of lesions, without apparent effects on normal lymphatics .

Role of Sirolimus in Treatment of Microcystic , Mixed Lymphatic and Vascular Malformations

efficacy of sirolimus in decreasing size of the lesion over time , by clinical exam of size lesion \& measurement of size of leesion by ultrasound \& MRI

Sohag University

Resident-pediatric surgery department-sohag hospital university

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Role of Sirolimus in Treatment of Microcystic , Mixed Lymphatic and Vascular Malformations	NCT06160739	Microcystic Lym... Combined Vascul... Vascular Malfor...	Sirolimus 1Mg O...	6 Months - 12 Years	Sohag University
Role of Sirolimus in Treatment of Microcystic , Mixed Lymphatic and Vascular Malformations	NCT06160739	Microcystic Lym... Combined Vascul... Vascular Malfor...	Sirolimus 1Mg O...	6 Months - 12 Years	Sohag University
Role of Sirolimus in Treatment of Microcystic , Mixed Lymphatic and Vascular Malformations	NCT06160739	Microcystic Lym... Combined Vascul... Vascular Malfor...	Sirolimus 1Mg O...	6 Months - 12 Years	Sohag University

Spots Global Cancer Trial Database for combined vascular malformation